Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Hsieh, Wang-Da Liu, Yu-Shan Huang, Yi-Jiun Lin, E. Hsieh, W. Lian, Charles Chen, R. Janßen, S. Shih, Chung-Guei Huang, I.-C. Tai, Shan-Chwen Chang (2021)
Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC—COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation studyEClinicalMedicine, 38
Einav Levin, Y. Lustig, C. Cohen, R. Fluss, V. Indenbaum, S. Amit, R. Doolman, K. Asraf, E. Mendelson, A. Ziv, C. Rubin, L. Freedman, Y. Kreiss, G. Regev-Yochay (2021)
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 MonthsThe New England Journal of Medicine
(2021)
Decline of antibody titers 3 months after two doses of BNT162b2 in non-immunocompromised adultsClin Microbiol Infect
R. Mallory, N. Formica, S. Pfeiffer, Bethanie Wilkinson, A. Marcheschi, G. Albert, H. Mcfall, Michelle Robinson, J. Plested, Mingzhu Zhu, S. Cloney-Clark, Bin Zhou, G. Chau, A. Robertson, Sonia Maciejewski, Gale Smith, N. Patel, G. Glenn, F. Dubovsky (2021)
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
(2022)
COVID-19 Dashboard by the Centre for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https:// coronavirus.jhu.edu/map.html
(Mallory R, Formica N, Pfeiffer S, et al. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2 randomized placebo-controlled trial. medRxiv 2021.12.23.21267374. 10.1101/2021.12.23.2126737.)
Mallory R, Formica N, Pfeiffer S, et al. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2 randomized placebo-controlled trial. medRxiv 2021.12.23.21267374. 10.1101/2021.12.23.2126737.Mallory R, Formica N, Pfeiffer S, et al. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2 randomized placebo-controlled trial. medRxiv 2021.12.23.21267374. 10.1101/2021.12.23.2126737., Mallory R, Formica N, Pfeiffer S, et al. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2 randomized placebo-controlled trial. medRxiv 2021.12.23.21267374. 10.1101/2021.12.23.2126737.
SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing: Update on hospitalization and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529)
(Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization. bioRxiv. 2021.12.14.472630. 10.1101/2021.12.14.472630.)
Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization. bioRxiv. 2021.12.14.472630. 10.1101/2021.12.14.472630.Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization. bioRxiv. 2021.12.14.472630. 10.1101/2021.12.14.472630., Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization. bioRxiv. 2021.12.14.472630. 10.1101/2021.12.14.472630.
(UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing: Update on hospitalization and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529). December 31, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1044481/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf. Retrieved January 3, 2022)
UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing: Update on hospitalization and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529). December 31, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1044481/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf. Retrieved January 3, 2022UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing: Update on hospitalization and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529). December 31, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1044481/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf. Retrieved January 3, 2022, UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing: Update on hospitalization and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529). December 31, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1044481/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf. Retrieved January 3, 2022
M. Miller (2010)
AgencyChange: The Magazine of Higher Learning, 42
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
(2021)
OUP accepted manuscriptClinical Infectious Diseases
D. Khoury, D. Cromer, A. Reynaldi, T. Schlub, A. Wheatley, J. Juno, K. Subbarao, S. Kent, J. Triccas, M. Davenport (2021)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 27
N. Doria-Rose, M. Suthar, M. Makowski, S. O'connell, A. McDermott, B. Flach, J. Ledgerwood, J. Mascola, B. Graham, Bob Lin, S. O'dell, S. Schmidt, A. Widge, V. Edara, E. Anderson, L. Lai, K. Floyd, N. Rouphael, V. Zarnitsyna, P. Roberts, M. Makhene, Wendy Buchanan, C. Luke, J. Beigel, L. Jackson, K. Neuzil, H. Bennett, B. Leav, J. Albert, Pratap Kunwar (2021)
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19The New England Journal of Medicine, 384
D. Planas, Nell Saunders, P. Maes, F. Guivel-Benhassine, C. Planchais, Julian Buchrieser, William Bolland, F. Porrot, I. Staropoli, F. Lemoine, H. Péré, D. Veyer, J. Puech, Julien Rodary, Guy Baela, S. Dellicour, J. Raymenants, Sarah Gorissen, Caspar Geenen, B. Vanmechelen, Tony Wawina-Bokalanga, Joan Martí-Carrerasi, L. Cuypers, A. Sève, L. Hocqueloux, T. Prazuck, F. Rey, Etienne Simon-Lorrière, T. Bruel, H. Mouquet, E. André, O. Schwartz (2021)
Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralizationbioRxiv
S. Hsieh, M. Liu, Yen-Hsu Chen, Wen-Sen Lee, Shinn-Jang Hwang, S. Cheng, W. Ko, K. Hwang, Ning-Chi Wang, Yu-Lin Lee, Yi-Ling Lin, S. Shih, Chung-Guei Huang, Chun-Che Liao, Jian-Jong Liang, Chih-Shin Chang, Charles Chen, C. Lien, I.-C. Tai, Tzou-Yien Lin (2021)
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in TaiwanThe Lancet. Respiratory Medicine, 9
(Lien CE, Kuo TY, Lin YJ, et al. Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. Clin Infect Dis. 2021;ciab711. 10.1093/cid/ciab711.)
Lien CE, Kuo TY, Lin YJ, et al. Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. Clin Infect Dis. 2021;ciab711. 10.1093/cid/ciab711.Lien CE, Kuo TY, Lin YJ, et al. Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. Clin Infect Dis. 2021;ciab711. 10.1093/cid/ciab711., Lien CE, Kuo TY, Lin YJ, et al. Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. Clin Infect Dis. 2021;ciab711. 10.1093/cid/ciab711.
(Taiwan Centers for Disease Control. V-Watch Bulletin Report, December 21, 2021. https://www.cdc.gov.tw/File/Get/paX3nGQmQ3qQo-BUQKMShQ. Accessed March 9, 2022.)
Taiwan Centers for Disease Control. V-Watch Bulletin Report, December 21, 2021. https://www.cdc.gov.tw/File/Get/paX3nGQmQ3qQo-BUQKMShQ. Accessed March 9, 2022.Taiwan Centers for Disease Control. V-Watch Bulletin Report, December 21, 2021. https://www.cdc.gov.tw/File/Get/paX3nGQmQ3qQo-BUQKMShQ. Accessed March 9, 2022., Taiwan Centers for Disease Control. V-Watch Bulletin Report, December 21, 2021. https://www.cdc.gov.tw/File/Get/paX3nGQmQ3qQo-BUQKMShQ. Accessed March 9, 2022.
(2021)
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialLancet., 398
A. Erice, D. Varillas-Delgado, C. Caballero (2021)
Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adultsClinical Microbiology and Infection, 28
A. Antia, H. Ahmed, A. Handel, N. Carlson, Ian Amanna, R. Antia, M. Slifka (2018)
Heterogeneity and longevity of antibody memory to viruses and vaccinesPLoS Biology, 16
H. Togt (2003)
Publisher's NoteJ. Netw. Comput. Appl., 26
(Dong E, Du H, Gardner L. COVID-19 Dashboard by the Centre for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html. Accessed March 6, 2022.)
Dong E, Du H, Gardner L. COVID-19 Dashboard by the Centre for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html. Accessed March 6, 2022.Dong E, Du H, Gardner L. COVID-19 Dashboard by the Centre for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html. Accessed March 6, 2022., Dong E, Du H, Gardner L. COVID-19 Dashboard by the Centre for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html. Accessed March 6, 2022.
I. Nemet, L. Kliker, Y. Lustig, N. Zuckerman, O. Erster, C. Cohen, Y. Kreiss, S. alroy-Preis, G. Regev-Yochay, E. Mendelson, M. Mandelboim (2021)
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron InfectionThe New England Journal of Medicine
D. Cromer, J. Juno, D. Khoury, A. Reynaldi, A. Wheatley, S. Kent, M. Davenport (2021)
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfectionNature Reviews. Immunology, 21
IntroductionMVC-COV1901 is a protein subunit COVID-19 vaccine based on the stable prefusion spike protein S-2P adjuvanted with CpG 1018 and aluminum hydroxide. Interim results of a phase 2 clinical trial demonstrated favorable safety profile and immunogenicity and the vaccine has been authorized for use in Taiwan. However, waning antibody levels after immunization and variants of concern (VoC) could negatively impact vaccine-induced neutralization of virus. In this extension to the phase 1 clinical study we investigated a three-dose regimen of MVC-COV1901 for durability of antibody levels and virus neutralization capacity, including neutralization of the Omicron variant.MethodsForty-five healthy adults from 20 to 49 years of age were divided into three groups of 15 participants receiving two doses of either low dose (LD), medium dose (MD), or high dose (HD) of MVC-COV1901. Six months after the second dose (day 209), a third MD dose of MVC-COV1901 was administered to the LD and MD groups and a HD dose was given to the HD group. Safety was followed for up to 28 days after the booster dose by monitoring incidences of adverse events (AE). Immunogenicity and antibody persistence for up to 6 months after the booster dose were assessed by neutralizing assay with the wild-type (Wuhan) SARS-CoV-2 virus. To examine the immunogenicity of booster dose against variants, neutralizing assays were carried out with the Alpha, Beta, and Delta variant viruses and the Omicron variant pseudovirus using samples from 4 weeks after the booster dose.ResultsAdverse reactions after the booster dose were mostly mild and comparable to that of the first two doses. Compared to day 209, neutralizing antibodies were increased by 10.3–28.9 times at 4 weeks after the booster. During the 6-month follow-up after the booster, the rate of decline of neutralizing antibody level was much less than that after the second dose. Three doses of MVC-COV1901 also improved antibody-mediated neutralization of Alpha, Beta, and Delta variants as well as the Omicron variant pseudovirus.ConclusionOur data showed increased persistence of neutralizing antibodies and enhancement of immunogenicity against VoCs offered after a third dose of MVC-COV1901.Trial RegistrationClinicalTrials.gov identifier NCT04487210.
Infectious Diseases and Therapy – Springer Journals
Published: Aug 1, 2022
Keywords: Booster vaccination; COVID-19; MVC-COV1901; SARS-CoV-2; SARS-CoV-2 vaccine
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.